Customs and Border Protection (CBP) has issued operational guidance regarding the reduction of additional ad valorem duty rates from 10% to 0% for patented pharmaceuticals and related ingredients originating from the United Kingdom. This adjustment is enacted pursuant to Presidential Proclamation 11020, taking effect for goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. ET on July 31.
Classification and Filing Instructions
Importers, customs brokers, and entry filers must update their entry processes to align with the regulatory changes under Harmonized Tariff Schedule of the United States (HTSUS) provisions:
-
HTSUS Heading 9903.04.63: Applies strictly to qualifying patented pharmaceutical articles and associated ingredients that are products of the United Kingdom, as defined under U.S. notes 40(c) and 40(g) to subchapter III.
-
Duty Rate: 0% additional ad valorem duty.
-
Reference Material: Filers should consult CSMS #69395344 for the complete mapping of Chapters 1–97 HTSUS classifications corresponding to heading 9903.04.63, as well as supplementary Chapter 99 headings established under Proclamation 11020.
Support and Compliance Contacts
Supply chain and compliance professionals managing affected entries should note the following resources for operational assistance:
-
Entry Filing Inquiries (Section 232 / Trade Remedies): Contact the CBP Trade Remedy Branch at
[email protected] -
System Errors (Entry Summary Processing): Reach out directly to your assigned CBP client representative or the Automated Commercial Environment (ACE) Help Desk.
Industry stakeholders and trade associations will continue to track implementation updates, automated system adjustments, and further enforcement directives to ensure seamless supply chain execution.
